title: Biologics in vasculitides: Where do we stand, where do we go from now?
abstract: Biological agents represent a valid therapeutic option in patients with severe and/or relapsing vasculitis. Over the last years, some of these agents have become an established therapy (such as RTX in AAV or IFX for ocular BD), and some appear to hold promise to become so. In addition, there are a number of drugs in the pipeline that may contribute to further improve the prognosis of vasculitis. As the range of medications available for vasculitis widens, the need will also increase to define the best treatment schemes as well as to identify those patients that may benefit most from biological agents.
authors.affiliation: Istituto di Ricovero e Cura a Carattere Scientifico, Azienda Ospedaliera ASMN, department of internal medicine, rheumatology unit, viale Risorgimento, 80, 42123 Reggio Emilia, Italy.
authors.forename: Giulia
authors.initials: G
authors.lastname: Pazzola
authors.affiliation: Istituto di Ricovero e Cura a Carattere Scientifico, Azienda Ospedaliera ASMN, department of internal medicine, rheumatology unit, viale Risorgimento, 80, 42123 Reggio Emilia, Italy.
authors.forename: Francesco
authors.initials: F
authors.lastname: Muratore
authors.affiliation: Istituto di Ricovero e Cura a Carattere Scientifico, Azienda Ospedaliera ASMN, department of internal medicine, rheumatology unit, viale Risorgimento, 80, 42123 Reggio Emilia, Italy.
authors.forename: Nicolò
authors.initials: N
authors.lastname: Pipitone
authors.affiliation: Istituto di Ricovero e Cura a Carattere Scientifico, Azienda Ospedaliera ASMN, department of internal medicine, rheumatology unit, viale Risorgimento, 80, 42123 Reggio Emilia, Italy. Electronic address: Salvarani.carlo@asmn.re.it.
authors.forename: Carlo
authors.initials: C
authors.lastname: Salvarani
mesh_terms: D000069594:Abatacept; D056648:Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / Q000188:drug therapy; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001528:Behcet Syndrome / Q000188:drug therapy; D001688:Biological Products / Q000627:therapeutic use*; D000068800:Etanercept; D005544:Forecasting; D013700:Giant Cell Arteritis / Q000188:drug therapy; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use; D007074:Immunoglobulin G / Q000627:therapeutic use; D015337:Multicenter Studies as Topic; D016032:Randomized Controlled Trials as Topic; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D013625:Takayasu Arteritis / Q000188:drug therapy; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014657:Vasculitis / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D001688:Biological Products; D018796:Immunoconjugates; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069594:Abatacept; D000068800:Etanercept